Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.

Andy Rawstron, Fiona Bennet, Sheila O'Connor, Marwan Cheng Kuang Kwok, James Fenton, Marieth Plummer, Ruth de Tute, Roger Owen, Steven Richard, Andrew Jack, Peter Hillmen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The 2007 IWCLL guidelines indicate that a diagnosis of Chronic Lymphocytic Leukemia (CLL) requires a B-cell count above 5,000/μL in the absence of other features; below this level the diagnosis is Monoclonal B-cell Lymphocytosis (MBL). There is little outcome data for MBL patients and it is not clear whether the detection of low levels of CLL cells, seen in 3% of the general population, is of clinical relevance. We have therefore investigated two hospital populations: the first with normal blood counts and no history of cancer; and the second MBL patients referred for investigation of a current or prior lymphocytosis.
Original languageEnglish
Title of host publicationBlood
PublisherAmerican Society of Hematology
Pages749
Volume110
DOIs
Publication statusPublished - 16 Nov 2007

Publication series

NameBlood
PublisherAmerican Society of Hematology
ISSN (Print)0006-4971

Fingerprint

Dive into the research topics of 'Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.'. Together they form a unique fingerprint.

Cite this